Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Next Generation Antibody Drug Market Growth Performance Trended Historically, And What Lies Ahead?

There has been a rapid increase in the size of the next-generation antibody drug market in the recent past. The market growth is projected to escalate from a 2024 value of $14.26 billion to $16.4 billion in 2025, achieving a compound annual growth rate (CAGR) of 15.0%. Factors contributing to this increase during the historical timeframe include a heightened demand for targeted therapies, a rise in cancer cases, a growing preference for immuno-oncology therapies, an amplified focus on autoimmune diseases, and an expanding regulatory support.

In the coming years, the market size of next-generation antibody drugs is anticipated to witness a rapid expansion. By 2029, it is projected to reach $29.08 billion, with a Compound Annual Growth Rate (CAGR) of 15.4%. Various factors contributing to this growth during the forecast period include an increased demand for tailor-made medicine, expansion of the drug pipeline, heightened healthcare awareness, more research collaborations, and an aging population. Key trends in this period include improvements in antibody-drug conjugates, technological evolution of bispecific antibodies, the incorporation of next-generation sequencing, progress in protein engineering, and advancement in integrating gene therapy.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24335&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Next Generation Antibody Drug Market?

The surge in attention towards personalized medicine is projected to trigger the expansion of the next-generation antibody-drug market in the future. Personalized medicine is a healthcare strategy that crafts remedies based on the patient’s unique genetic, environmental, and lifestyle aspects, securing more accurate and specific treatments. This approach is becoming more prominent due to the progressive developments in genomic sequencing, promoting more detailed diagnosis and specific treatment plans. Next-generation antibody medications reinforce the spotlight on personalized medicine by facilitating the formation of targeted therapies attuned to patients’ individual genetic structures and disease features, enhancing effectiveness and reducing negative impacts. For example, in February 2024, as reported by the Personalized Medicine Coalition, an organization in the US championing the incorporation of personalized medicine, the US Food and Drug Administration (FDA) greenlit 16 fresh personalized remedies for patients with rare diseases in 2023, a considerable rise from the 6 approved in 2022. As such, the augmented concentration on personalized medicine fuels the growth of the next-generation antibody drug market.

Which Key Market Segments Comprise the Next Generation Antibody Drug Market and Drive Its Revenue Growth?

The next generation antibody drug market covered in this report is segmented –

1) By Product Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types

2) By Mechanism Of Action: Checkpoint Inhibitors, Immune Modulators, Receptor Blockers, Targeted Cytotoxic Agents, Neutralizing Antibodies

3) By Delivery Method: Intravenous (IV) Administration, Subcutaneous Administration, Intramuscular Administration, Oral Formulations, Transdermal Delivery Systems

4) By Application: Oncology, Autoimmune Diseases, Infectious Diseases, Other Applications

5) By End User: Hospitals, Research Institutes, Specialty Clinics, Other End Users

Subsegments:

1) By Monoclonal Antibodies: Human Monoclonal Antibodies, Murine Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies

2) By Bispecific Antibodies: Checkpoint Inhibitor-Based Bispecifics, Bispecific Antibodies For Cytokine Modulation, Bispecific Antibodies With Extended Half-Life Technologies

3) By Antibody-Drug Conjugates: Cleavable Linker Antibody-Drug Conjugates, Non-Cleavable Linker Antibody-Drug Conjugates, Site-Specific Conjugated Antibody-Drug Conjugates

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=24335&type=smp

Which Areas Are Leading Regions in the Next Generation Antibody Drug Market Expansion Across the Globe?

North America was the largest region in the next generation antibody drug market in 2024. The regions covered in the next generation antibody drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theNext Generation Antibody Drug Market Over the Coming Years?

Key players in the future antibody pharmaceutical market are prioritizing the creation of cutting-edge solutions like antibody-drug conjugates to augment targeted cancer treatments, boost therapeutic effectiveness, and lower systemic toxicity. An antibody-drug conjugate (ADC) is a type of targeted cancer treatment that merges a monoclonal antibody with a cytotoxic drug via a linkage. This allows for the careful delivery of the medicine to cancerous cells while preventing damage to healthy cells. As an example, in January 2024, BioNTech SE, a biotech firm from Germany, collaborated with Duality Biologics (Suzhou) Co. Ltd., a Chinese pharmaceutical company, and received a Fast Track designation from the U.S. Food and Drug Administration (FDA) for their ADC candidate called BNT325/DB-1305, targeting platinum-resistant ovarian cancer. The drug employs DualityBio’s breakthrough DITAC (Duality Immune Toxin Antibody Conjugates) technology, amalgamating a highly potent cytotoxic payload with a monoclonal antibody, ensuring accuracy in the delivery of treatment specifically to cancer cells. The drug BNT325/DB-1305 has a distinct advantage in its ability to accurately focus on cancer cells while safeguarding healthy tissues, improving the effectiveness of the treatment and minimizing adverse reactions.

View the full report here:

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-drug-global-market-report

How Is the Next Generation Antibody Drug Market Conceptually Defined?

Next-generation antibody drugs refer to advanced therapeutic antibodies designed to target specific antigens with higher precision and efficacy, often incorporating innovative technologies such as bispecific antibodies or antibody-drug conjugates. These drugs aim to improve disease treatment outcomes by enhancing targeting capabilities and minimizing side effects.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24335

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model